Diagnostic and therapeutic management in gastroesophageal reflux disease: consensus of the Polish Society of Gastroenterology

Świdnicka-Siergiejko, Agnieszka Katarzyna; Marek, Tomasz; Waśko−Czopnik, Dorota; Gąsiorowska, Anita; Skrzydło-Radomańska, Barbara; Janiak, Maria; Reguła, Jarosław; Rydzewska, Grażyna; Wallner, Grzegorz; Dabrowski, A

doi:10.20452/pamw.16196

Cited by 4 publications

(3 citation statements)

References 214 publications

(426 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Mediterranean diet is also beneficial for patients with gastroesophageal reflux disease. 65 Thus, following the Mediterranean diet provides numerous health -promoting effects, which are very well documented. Therefore, the European Society of Cardiology recommends adopting the Mediterranean or similar diet to lower the risk of CVD (class of recommendation, I; level of evidence, A).…”

Section: Mediterranean Diet and Winementioning

confidence: 99%

Alcohol, health loss and mortality: can wine really save the good name of moderate alcohol consumption?

Surma,

Gajos

2024

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

health loss, and mortality 1 diuretic, and antidiarrheic properties around the 4th century BC. For ages, until the 20th century, alcohol was widely used as a medicinal remedy, as seen in the New Testament's parable of the Good Samaritan, where wine was applied to dress wounds. 1,2 In Poland, the first vineyards appeared 1000 years ago on the Wawel Hill. Wine is a drink resulting from alcoholic fermentation, obtained exclusively from fresh grapes or their juice (so -called must), with a possible addition of permitted substances, produced in accordance with established enological processes. 1,2 It is believed that fermented drinks were consumed as far back as in the Late Neolithic period. The earliest surviving texts mentioning beer brewing and consumption date back to around 4000 BC from Mesopotamia. 1,2 Brief history of alcohol consumption Determining the exact origins of alcohol consumption is challenging. The history of wine began in Georgia 8000 years ago. Hippocrates did not recommend wine to children and pregnant women, and he expressed his philosophy regarding the beneficial effects of wine in a well -known principle: "Wine is fit for man in a wonderful way provided that it is taken with good sense by the sick as well as the healthy." Galen, who successfully developed this theory, also considered wine an important element of medical therapy. In his work De antidotis, he also mentioned many wine -based antidotes against poisons commonly used at that time. 1,2 Growing popularity of alcohol consumption was linked to its perceived medicinal properties. Aristotle noted wine's sedative, analgesic,

show abstract

Section: Mediterranean Diet and Winementioning

confidence: 99%

Alcohol, health loss and mortality: can wine really save the good name of moderate alcohol consumption?

Surma,

Gajos

2024

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

show abstract

“…Surgical treatment is not well established in patients with extraesophageal symptoms and is not recommended in these cases (58,100) . Numerous studies have examined therapeutic options when clinical versus surgical treatment is in question (99)(100)(101)(102)(103)(104) having observed that the frequency of endoscopic fundoplication has decreased in recent years (105) .…”

Section: Commentmentioning

confidence: 99%

Brazilian Clinical Guideline for the Therapeutic Management of Gastroesophageal Reflux Disease (Brazilian Federation of Gastroenterology, Fbg)

MORAES-FILHO,

DOMINGUES,

CHINZON

2024

Arq. Gastroenterol.

View full text Add to dashboard Cite

Background: Gastroesophageal Reflux Disease (GERD) is a prevalent condition in Brazil, affecting 12% to 20% of the urban population, with significant implications for patient quality of life and potential for complications. Objective: This paper focuses on the recent update of the Brazilian guidelines for GERD, a necessary revision due to advancements in knowledge and practice since the last publication over a decade ago. The update pays particular attention to the role and safety of proton pump inhibitors (PPIs), acknowledging the growing concerns about their long-term use, adverse events, and overprescription. Methods: The methodology of the guideline update involved an extensive literature review in multiple languages (English, French, Italian, Spanish, and Portuguese), drawing from major databases such as Medline, Embase, and SciELO-Lilacs. Results: This comprehensive approach resulted in a carefully curated selection of studies, systematic reviews, and meta-analyses, specifically focusing on PPIs and other therapeutic strategies for GERD. The updated guidelines are presented in a user-friendly question-and-answer format, adhering to the PICO system (Population, Intervention, Comparison, Outcomes) for clarity and ease of interpretation. The recommendations are supported by robust scientific evidence and expert opinions, enhancing their practical applicability in clinical settings. To ensure the reliability and clarity of the recommendations, the GRADE system (Grading of Recommendations Assessment, Development, and Evaluation) was employed. This system categorizes the strength of recommendations as strong, weak, or conditional and classifies evidence quality as high, moderate, low, or very low. These classifications provide insight into the confidence level of each recommendation and the likelihood of future research impacting these guidelines. Conclusion: The primary aim of these updated guidelines is to offer practical, evidence-based advice for the management of GERD in Brazil, ensuring that healthcare professionals are equipped with the latest knowledge and tools to deliver optimal patient care.

show abstract

“…Unlike PPIs, P-CAB is a new type of highly efficient and selective gastric H+/K+-ATPase inhibitor that does not require activation in a strong acid environment to function. The greatest advantage of tegoprazan, a novel P-CAB, is its ability to bind to the K+ binding site of H+/K+-ATPase in a competitive and reversible manner without acid activation and without any conversion, exhibiting faster gastric acid inhibition than PPIs and almost complete inhibition of gastric acid secretion [ 9 , 14 ]. In addition, P-CAB-induced gastric acid inhibition is not affected by the ab initio synthesis of proton pumps in gastric lining cells, thus enabling faster maximal inhibition and longer duration of action, making P-CAB a novel, highly selective and efficient acid inhibitor [ 15 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of tegoprazan in the treatment of gastroesophageal reflux disease: A protocol for meta-analysis and systematic review

Zheng,

Yuan,

Liu

2024

PLoS ONE

View full text Add to dashboard Cite

Objective The incidence of gastroesophageal reflux disease (GERD) is increasing year by year, the clinical manifestations are complex and diverse, and the adverse effects of long-term use of proton pump inhibitors and gastrointestinal motility drugs have been of great concern in recent years. The effectiveness of tegoprazan in the treatment of GERD is still controversial. This protocol describes a systematic review and meta-analysis to evaluate the efficacy and safety of tegoprazan in the treatment of gastroesophageal reflux disease. Methods PubMed, Embase, Cochrane Library and Web of Science will be searched from the database inception to 1 March 2023. All randomized controlled trials related to tegoprazan for GERD will be included. Extracted data will include publication details, basic information, demographic data, intervention details and patient outcomes. The primary outcome will be complete resolution of major symptoms, complete resolution of heartburn, proportion of heartburn-free days, chronic cough, hoarseness, and adverse events. Risk of bias will be assessed using the Cochrane Collaboration’s tool for assessing risk of bias. Article selection, data extraction and risk of bias assessment will be performed in duplicate by two independent reviewers. If the meta-analysis is precluded, we will conduct a descriptive synthesis using a best-evidence synthesis approach. Discussion The results of this study will provide reliable evidence to evaluate the efficacy and safety of tegoprazan in the treatment of GERD and help patients, physicians and clinical investigators choose the most appropriate treatment.

show abstract

Diagnostic and therapeutic management in gastroesophageal reflux disease: consensus of the Polish Society of Gastroenterology

Cited by 4 publications

References 214 publications

Alcohol, health loss and mortality: can wine really save the good name of moderate alcohol consumption?

Alcohol, health loss and mortality: can wine really save the good name of moderate alcohol consumption?

Brazilian Clinical Guideline for the Therapeutic Management of Gastroesophageal Reflux Disease (Brazilian Federation of Gastroenterology, Fbg)

Efficacy and safety of tegoprazan in the treatment of gastroesophageal reflux disease: A protocol for meta-analysis and systematic review

Contact Info

Product

Resources

About